Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Diabetologia. 2013 Aug 10;56(11):10.1007/s00125-013-3009-7. doi: 10.1007/s00125-013-3009-7

Fig. 5.

Fig. 5

Effect of systemic B2AR agonist on the development of insulin-induced hypoglycaemia. Plasma glucose concentration in rats receiving peripheral injection of the vehicle (control; n=4), and the B2AR agonist formoterol (n=4) during insulin-induced hypoglycaemia. The arrow indicates the time at which the B2AR agonist was delivered. Circles, B2AR agonist; squares, control. ****p<0.0001 vs control